Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Aducanumab lacks substantial evidence of efficacy for Alzheimer's treatment, a US FDA panel said.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers